<i>In vivo</i> efficacy of enmetazobactam combined with cefepime in a murine pneumonia model induced by OXA-48-producing <i>Klebsiella pneumoniae</i>.

ABSTRACT: Cefepime/enmetazobactam is a new β-lactam/β-lactamase inhibitor combination with broad-spectrum activity against multidrug-resistant Enterobacterales, including OXA-48-producing isolates. Furthermore, cefepime and enmetazobactam have demonstrated similar and excellent intrapulmonary penetration, supporting the use of this new antibiotic combination in the treatment of hospital-acquired pneumonia. This study evaluated the in vivo efficacy of cefepime/enmetazobactam in a murine neutropenic pneumonia model infected with various OXA-48-producing K. pneumoniae strains. Mice were subcutaneously administered with cefepime (100 mg/kg/q2h), alone or combined with enmetazobactam (30 mg/kg/q2h), or intraperitoneally with meropenem (100 mg/kg/q2h) at 2 h post-infection. Mice were euthani

SUBMITTER: Albac S 

PROVIDER: S-EPMC11619402 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature